Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma

Table 3 Analysis of prognostic factors

Characteristics	OS		TTP
	HR	P value	HR	P value
Univariate analysis
Gender
Male vs female	0.870	0.804	0.87	0.793
Age, yr
< 60 vs≥ 60	0.090	0.023	0.46	0.143
Primary liver mass control
Yes vs no	4.220	0.006	3.56	0.006
Disease control
PR + SD vs PD	5.960	< 0.001	45.3	< 0.001
Multivariate analysis
Age, yr
< 60 vs≥ 60	0.074	0.017	0.91	0.800
Primary liver mass control
Yes vs no	3.660	0.026	1.38	0.540
Disease control
PR + SD vs PD	4.310	0.011	36.69	0.001

In univariate and multivariate analysis, patients with age over than 60 or stable primary liver mass showed the better OS and TTP. The patients with partial response or stable disease also had better survival outcome but not in time to progression in multivariate analysis. PR: Partial response; PD: Progressive disease. OS: Overall survival: TTP: Time to progression.